TrialThe Lancet. Oncology2017

Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study.

Van K Morris et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.